Cargando…

Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C

BACKGROUND: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)- α and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. This makes it necessary to predict patient outcome so as to improve the accurac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onomoto, Koji, Morimoto, Shiho, Kawaguchi, Takahisa, Toyoda, Hidenori, Tanaka, Masami, Kuroda, Masahiko, Uno, Kazuko, Kumada, Takashi, Matsuda, Fumihiko, Shimotohno, Kunitada, Fujita, Takashi, Murakami, Yoshiki
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094385/ https://www.ncbi.nlm.nih.gov/pubmed/21603632 http://dx.doi.org/10.1371/journal.pone.0019799

Ejemplares similares

The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families
por: Murakami, Yoshiki, et al.
Publicado: (2011)

Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C
por: Murakami, Yoshiki, et al.
Publicado: (2010)

High‐level expression of STING restricts susceptibility to HBV by mediating type III IFN induction
por: Dansako, Hiromichi, et al.
Publicado: (2018)

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
por: Toyoda, Hidenori, et al.
Publicado: (2012)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis
por: Murakami, Yoshiki, et al.
Publicado: (2013)

Repressive Effect of the nef cDNA of Human Immunodeficiency Virus Type 1 on the Promoter Activity of the Viral Long Terminal Repeat
por: Mori, Shigehisa, et al.
Publicado: (1990)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Transnasal Endoscope Locked in a Bent Position Causing Difficult Withdrawal
por: Toyoda, Hidenori, et al.
Publicado: (2014)

Critical Role of Interferon-α Constitutively Produced in Human Hepatocytes in Response to RNA Virus Infection
por: Tsugawa, Yoji, et al.
Publicado: (2014)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Cyclophilin and Viruses: Cyclophilin as a Cofactor for Viral Infection and Possible Anti-Viral Target
por: Watashi, Koichi, et al.
Publicado: (2007)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis
por: Oeda, Satoshi, et al.
Publicado: (2012)

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients
por: Fujita, Koji, et al.
Publicado: (2018)

Hepatitis C Virus Core Protein Abrogates the DDX3 Function That Enhances IPS-1-Mediated IFN–Beta Induction
por: Oshiumi, Hiroyuki, et al.
Publicado: (2010)

Helper virus-independent trans-replication of hepatitis C virus-derived minigenome
por: Zhang, Jing, et al.
Publicado: (2007)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)–CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report
por: Jiang, Weimin, et al.
Publicado: (2014)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention
por: Ohkoshi, Shogo, et al.
Publicado: (2010)

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
por: Sherstoboev, E. Yu., et al.
Publicado: (2022)

Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C
por: Numata, Makoto, et al.
Publicado: (2010)

Ick Suppresses Gene Expression from Various Promoters Including Human T‐Cell Leukemia Virus Type I Promoter
por: Ohta, Masataka, et al.
Publicado: (1990)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
por: Nishikawa, Hiroki, et al.
Publicado: (2012)

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
por: Kawaguchi, Takumi, et al.
Publicado: (2019)

Angiotensin–Converting Enzyme (ACE) 1 Gene Polymorphism and Phenotypic Expression of COVID-19 Symptoms
por: Yamamoto, Naoki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q7a6flrg93j6h56a3qmhkld9af